Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Claims for obesity were noted in 31% (n = 426) of patients in the combined population, vitamin D deficiency in 26% (n = 349), renal disease in 21% (n = 280), hypertension in 18% (n = 249), depression in 18% (n = 247), and fracture in 17% (n = 232), with 15% (n = 197) having claims associated with codes for hearing loss (Fig. 2).
Source: Morbidities and other complications. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Cohort study.
Cohort study
Examines exposures and outcomes over time within a defined group.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
This retrospective cohort study used Komodo Health’s Healthcare Map™, a de-identified patient-level claims database.
Source: Abstract.
In each dataset patients were included if they had ≥ 1 claim for familial hypophosphatemia or other disorders of phosphate metabolism within the study period (International Classification of Diseases, 10th Edition, Clinical Modification [ICD-10-CM] E83.31, E83.39, ICD-9-CM 2753) and ≥ 1 claim for burosumab between 01-Apr-2018 and 30-Jun-2022.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Real-world characteristics & disease history of patients with X-linked hypophosphatemia before treatment with burosumab
Cohort study · Archives of Osteoporosis · 2025
Original publication title
Real-world characteristics & disease history of patients with X-linked hypophosphatemia before treatment with burosumab
© The Author(s) 2025
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What objectives does the paper state?
To examine the characteristics and disease history of real-world patients with X-linked hypophosphatemia (XLH) in the United States, prior to initiating burosumab.
Source: PurposeAbstract: What methods does the paper describe?
This retrospective cohort study used Komodo Health’s Healthcare Map™, a de-identified patient-level claims database. Included patients had ≥ 1 claim for familial hypophosphatemia between 01-Jan-2015 and 30-Jun-2022 (the study period) and ≥ 1 claim for burosumab between 01-Apr-2018 and 30-Jun-2022. The index date was the date of first burosumab claim. Patient demographics were measured at index; disease history was measured over the pre-index period and stratified by age. All variables were evaluated descriptively.
Source: MethodsAbstract: Summary
In a United States claims database, 1,358 persons with familial hypophosphatemia who began treatment with burosumab were identified. Prior to treatment, high rates of several morbidities were coded including osteoarthritis, fractures, enthesopathy, spinal stenosis, hypertension, depression and opioid use, which generally increased with age, emphasizing disease burden throughout the lifespan.
Source: SummaryAbstract: Results
1,358 patients were included (mean age 23.5 ± 19.1 years, 847 [62%] female); 720 patients (53%) were aged < 18 years. Prior to index, patients had high levels of XLH-related morbidities. Most XLH-related morbidities appeared in the youngest age groups, and the prevalence was generally greater among the older age groups. For example, arthralgia was found in 57 patients (12%) aged ≤ 11 years and 123 patients (69%) aged ≥ 50 years. Opioid use increased with age (173 patients [24%] aged < 18 years; 328 [51%] ≥ 18 years).
Physical therapy use was observed across age groups (126 patients [18%] aged < 18 years; 253 [40%] ≥ 18 years).
Source: ResultsAbstract: Conclusions
At initiation of burosumab, over half of patients with XLH were < 18 years of age. Claims indicated a high prevalence of XLH-related morbidities, which began at a young age and increased over time.
Source: ConclusionsAuthors’ abstract
Summary
In a United States claims database, 1,358 persons with familial hypophosphatemia who began treatment with burosumab were identified. Prior to treatment, high rates of several morbidities were coded including osteoarthritis, fractures, enthesopathy, spinal stenosis, hypertension, depression and opioid use, which generally increased with age, emphasizing disease burden throughout the lifespan.
Purpose
To examine the characteristics and disease history of real-world patients with X-linked hypophosphatemia (XLH) in the United States, prior to initiating burosumab.
Methods
This retrospective cohort study used Komodo Health’s Healthcare Map™, a de-identified patient-level claims database. Included patients had ≥ 1 claim for familial hypophosphatemia between 01-Jan-2015 and 30-Jun-2022 (the study period) and ≥ 1 claim for burosumab between 01-Apr-2018 and 30-Jun-2022. The index date was the date of first burosumab claim. Patient demographics were measured at index; disease history was measured over the pre-index period and stratified by age. All variables were evaluated descriptively.
Results
1,358 patients were included (mean age 23.5 ± 19.1 years, 847 [62%] female); 720 patients (53%) were aged < 18 years. Prior to index, patients had high levels of XLH-related morbidities. Most XLH-related morbidities appeared in the youngest age groups, and the prevalence was generally greater among the older age groups. For example, arthralgia was found in 57 patients (12%) aged ≤ 11 years and 123 patients (69%) aged ≥ 50 years. Opioid use increased with age (173 patients [24%] aged < 18 years; 328 [51%] ≥ 18 years).
Physical therapy use was observed across age groups (126 patients [18%] aged < 18 years; 253 [40%] ≥ 18 years).
Conclusions
At initiation of burosumab, over half of patients with XLH were < 18 years of age. Claims indicated a high prevalence of XLH-related morbidities, which began at a young age and increased over time.
Supplementary Information
The online version contains supplementary material available at 10.1007/s11657-025-01544-1.
Publication and source details
Original title: Real-world characteristics & disease history of patients with X-linked hypophosphatemia before treatment with burosumab
Kathryn M. Dahir; Zhiyi Li; Heather M. Heerssen; Ahmed Noman; Jeremy Kim; Yang Zhao; Erik A. Imel
Archives of Osteoporosis · 2025
© The Author(s) 20252025https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.http://dx.doi.org/10.13039/100016348Kyowa Kirin Pharmaceutical DevelopmentRepository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T05:12:27.666397+00:00
DOI: 10.1007/s11657-025-01544-1 · PMC12075324